624 related articles for article (PubMed ID: 27101816)
1. Treatment Patterns, Direct Cost of Biologics, and Direct Medical Costs for Rheumatoid Arthritis Patients: A Real-world Analysis of Nationwide Japanese Claims Data.
Sugiyama N; Kawahito Y; Fujii T; Atsumi T; Murata T; Morishima Y; Fukuma Y
Clin Ther; 2016 Jun; 38(6):1359-1375.e1. PubMed ID: 27101816
[TBL] [Abstract][Full Text] [Related]
2. Drug retention and discontinuation reasons between seven biologics in patients with rheumatoid arthritis -The ANSWER cohort study.
Ebina K; Hashimoto M; Yamamoto W; Ohnishi A; Kabata D; Hirano T; Hara R; Katayama M; Yoshida S; Nagai K; Son Y; Amuro H; Akashi K; Fujimura T; Hirao M; Yamamoto K; Shintani A; Kumanogoh A; Yoshikawa H
PLoS One; 2018; 13(3):e0194130. PubMed ID: 29543846
[TBL] [Abstract][Full Text] [Related]
3. Drug retention rates of second biologic agents after switching from tumor necrosis factor inhibitors for rheumatoid arthritis in Japanese patients on low-dose methotrexate or without methotrexate.
Kobayakawa T; Kojima T; Takahashi N; Hayashi M; Yabe Y; Kaneko A; Shioura T; Saito K; Hirano Y; Kanayama Y; Miyake H; Asai N; Funahashi K; Hirabara S; Hanabayashi M; Asai S; Ishiguro N
Mod Rheumatol; 2015 Mar; 25(2):251-6. PubMed ID: 25211402
[TBL] [Abstract][Full Text] [Related]
4. Medication effectiveness with the use of tumor necrosis factor inhibitors among Texas Medicaid patients diagnosed with rheumatoid arthritis.
Oladapo A; Barner JC; Lawson KA; Novak S; Rascati KL; Richards KM; Harrison DJ
J Manag Care Spec Pharm; 2014 Jul; 20(7):657-67. PubMed ID: 24967519
[TBL] [Abstract][Full Text] [Related]
5. Drug tolerability and reasons for discontinuation of seven biologics in 4466 treatment courses of rheumatoid arthritis-the ANSWER cohort study.
Ebina K; Hashimoto M; Yamamoto W; Hirano T; Hara R; Katayama M; Onishi A; Nagai K; Son Y; Amuro H; Yamamoto K; Maeda Y; Murata K; Jinno S; Takeuchi T; Hirao M; Kumanogoh A; Yoshikawa H
Arthritis Res Ther; 2019 Apr; 21(1):91. PubMed ID: 30971306
[TBL] [Abstract][Full Text] [Related]
6. Retention of tocilizumab and anti-tumour necrosis factor drugs in the treatment of rheumatoid arthritis.
Hishitani Y; Ogata A; Shima Y; Hirano T; Ebina K; Kunugiza Y; Shi K; Narazaki M; Hagihara K; Tomita T; Yoshikawa H; Tanaka T; Kumanogoh A
Scand J Rheumatol; 2013; 42(4):253-9. PubMed ID: 23470089
[TBL] [Abstract][Full Text] [Related]
7. Real-world retention rates of biologics in patients with rheumatoid arthritis.
Takami K; Tsuji S
Sci Rep; 2023 Dec; 13(1):21170. PubMed ID: 38040839
[TBL] [Abstract][Full Text] [Related]
8. Estimating effectiveness and cost of biologics for rheumatoid arthritis: application of a validated algorithm to commercial insurance claims.
Curtis JR; Schabert VF; Harrison DJ; Yeaw J; Korn JR; Quach C; Yun H; Joseph GJ; Collier DH
Clin Ther; 2014 Jul; 36(7):996-1004. PubMed ID: 25012729
[TBL] [Abstract][Full Text] [Related]
9. Cost of biologics per treated patient across immune-mediated inflammatory disease indications in a pharmacy benefit management setting: a retrospective cohort study.
Wu N; Lee YC; Shah N; Harrison DJ
Clin Ther; 2014 Aug; 36(8):1231-41, 1241.e1-3. PubMed ID: 25062652
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and Treatment Costs of Monotherapy with bDMARDs in the Treatment of Rheumatoid Arthritis in Patients Intolerant to or Inappropriate to Continue Treatment with Methotrexate.
Batticciotto A; Ravasio R; Riva M; Sarzi-Puttini P
Adv Ther; 2016 Aug; 33(8):1360-73. PubMed ID: 27376373
[TBL] [Abstract][Full Text] [Related]
11. Chronological changes in baseline disease activity of patients with rheumatoid arthritis who received biologic DMARDs between 2003 and 2012.
Sato E; Tanaka E; Ochiai M; Shimizu Y; Kobayashi A; Shidara K; Hoshi D; Sugimoto N; Inoue E; Seto Y; Nakajima A; Taniguchi A; Momohara S; Yamanaka H
Mod Rheumatol; 2015 May; 25(3):350-7. PubMed ID: 25619283
[TBL] [Abstract][Full Text] [Related]
12. Cost and effectiveness of biologics for rheumatoid arthritis in a commercially insured population.
Curtis JR; Chastek B; Becker L; Quach C; Harrison DJ; Yun H; Joseph GJ; Collier DH
J Manag Care Spec Pharm; 2015 Apr; 21(4):318-29. PubMed ID: 25803765
[TBL] [Abstract][Full Text] [Related]
13. Treatment Patterns and Costs in Biologic DMARD-Naive Patients with Rheumatoid Arthritis Initiating Etanercept or Adalimumab with or Without Methotrexate.
Tkacz J; Gharaibeh M; DeYoung KH; Wilson K; Collier D; Oko-Osi H
J Manag Care Spec Pharm; 2020 Mar; 26(3):285-294. PubMed ID: 32105179
[TBL] [Abstract][Full Text] [Related]
14. Economical impact associated with a biological therapy prioritization protocol in patients with rheumatoid arthritis in the Hospital of Sagunto.
Borrás-Blasco J; Casterá MD; Cortes X; Rosique-Robles JD; Abad FJ
Expert Opin Biol Ther; 2014 Nov; 14(11):1561-7. PubMed ID: 25303321
[TBL] [Abstract][Full Text] [Related]
15. Drug tolerability and reasons for discontinuation of seven biologics in elderly patients with rheumatoid arthritis -The ANSWER cohort study.
Ebina K; Hashimoto M; Yamamoto W; Hirano T; Hara R; Katayama M; Onishi A; Nagai K; Son Y; Amuro H; Yamamoto K; Maeda Y; Murata K; Jinno S; Takeuchi T; Hirao M; Kumanogoh A; Yoshikawa H
PLoS One; 2019; 14(5):e0216624. PubMed ID: 31067271
[TBL] [Abstract][Full Text] [Related]
16. Treatment patterns and annual biologic costs in US veterans with rheumatic conditions or psoriasis.
Sauer BC; Teng CC; He T; Leng J; Lu CC; Walsh JA; Shah N; Harrison DJ; Tang DH; Cannon GW
J Med Econ; 2016; 19(1):34-43. PubMed ID: 26337538
[TBL] [Abstract][Full Text] [Related]
17. Cost of biologic treatment persistence or switching in rheumatoid arthritis.
Gu T; Mutebi A; Stolshek BS; Tan H
Am J Manag Care; 2018 Jul; 24(8 Spec No.):SP338-SP345. PubMed ID: 30020745
[TBL] [Abstract][Full Text] [Related]
18. Cost per patient-year in response using a claims-based algorithm for the 2 years following biologic initiation in patients with rheumatoid arthritis.
Bonafede M; Johnson BH; Princic N; Shah N; Harrison DJ
J Med Econ; 2015 May; 18(5):376-89. PubMed ID: 25530318
[TBL] [Abstract][Full Text] [Related]
19. Tailored first-line biologic therapy in patients with rheumatoid arthritis, spondyloarthritis, and psoriatic arthritis.
Cantini F; Niccoli L; Nannini C; Cassarà E; Kaloudi O; Giulio Favalli E; Becciolini A; Biggioggero M; Benucci M; Li Gobbi F; Grossi V; Infantino M; Meacci F; Manfredi M; Guiducci S; Bellando-Randone S; Matucci-Cerinic M; Foti R; Di Gangi M; Mosca M; Tani C; Palmieri F; Goletti D;
Semin Arthritis Rheum; 2016 Apr; 45(5):519-32. PubMed ID: 26607440
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of Real-World Experience with Tofacitinib Compared with Adalimumab, Etanercept, and Abatacept in RA Patients with 1 Previous Biologic DMARD: Data from a U.S. Administrative Claims Database.
Harnett J; Gerber R; Gruben D; Koenig AS; Chen C
J Manag Care Spec Pharm; 2016 Dec; 22(12):1457-1471. PubMed ID: 27882833
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]